Reprogramming of lipid metabolism to inhibit T cell senescence and enhance tumor immunotherapy

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 31st, 2026

Detected March 31st, 2026

Summary

The USPTO granted US Patent 12590309B2 to Saint Louis University covering compositions and methods for inhibiting T cell senescence through reprogramming lipid metabolism via group IVA phospholipase A2 inhibitors. The patent includes 13 claims relating to T cell immunotherapy applications including adoptive T cell therapies and checkpoint blockade combinations. Inventors are Guangyong Peng and Xia Liu.

View original document View source feed page

What changed

USPTO issued Patent 12590309B2 to Saint Louis University on March 31, 2026. The patent covers inhibitors of group IVA phospholipase A2 and their use in modulating lipid metabolism of effector T cells to abrogate T reg- and tumor cell-induced senescence. The 13 claims span compositions and methods for improving adoptive T cell therapies and enhancing T cell effector functions in vivo, including combination with checkpoint blockade therapies.

Patent holders and licensees should update IP portfolio records with the new patent number and claims scope. Entities developing T cell immunotherapies should conduct freedom-to-operate analyses to assess potential licensing needs. Research institutions may explore collaboration or licensing opportunities with Saint Louis University.

Source document (simplified)

← USPTO Patent Grants

Reprogramming of lipid metabolism to inhibit T cell senescence and enhance tumor immunotherapy

Grant US12590309B2 Kind: B2 Mar 31, 2026

Assignee

Saint Louis University

Inventors

Guangyong Peng, Xia Liu

Abstract

The present disclosure provides compositions and methods for inhibiting T cell senescence and improving T cell immunotherapies. In particular, inhibitors of group IV A phospholipase A2 are disclosed as useful in modulating the lipid metabolism of cells, in particular effector T cells, such that T reg- and tumor cell-induced cell senescence is abrogated. These methods may be employed with particular utility in adoptive T cell therapies and/or enhanced T cell effector functions in vivo, including those performed in combination with checkpoint blockade therapies.